LP002

DRUG4 trials

Sponsors

Taizhou HoudeAoke Biomedical Co., Ltd.

Conditions

Digestive System NeoplasmsMelanomaPrimary Mediastinal Large B-Cell Lymphoma (PMBCL)Small-cell Lung Cancer

Phase 1

A Study of HX008 Plus LP002 for the Treatment of Patients With Advanced Melanoma

Taizhou HoudeAoke Biomedical Co., Ltd.Melanoma

Start: 2020-08-20End: 2022-08-20Target: 63Updated: 2021-02-16

A Study of LP002 for the Treatment of Patients With Malignant Digestive System Neoplasms

Taizhou HoudeAoke Biomedical Co., Ltd.Digestive System Neoplasms

Start: 2019-06-17End: 2022-06-30Target: 94Updated: 2021-02-16

Phase 2

Study of LP002 for the Treatment of Patients With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma

Taizhou HoudeAoke Biomedical Co., Ltd.Primary Mediastinal Large B-Cell Lymphoma (PMBCL)

Start: 2020-12-30End: 2023-05-30Target: 69Updated: 2020-10-23

Study of LP002 in Combination With Chemotherapy for Patients With Extensive Stage Small Cell Lung Cancer

Taizhou HoudeAoke Biomedical Co., Ltd.Small-cell Lung Cancer

Start: 2020-12-02End: 2022-08-01Target: 46Updated: 2021-02-05

Related Papers

Perioperative chemotherapy with LP002, an anti-PD-L1 antibody, in patients with resectable gastric and gastroesophageal junction cancer: A prospective, open-label, phase Ib trial.

Journal of Clinical Oncology2022-06-016 citations